April 18, 2017: Hearing vague takeover rumors circulating about Sarepta Therapeutics. The rumor is that Alexion could be interested in acquiring the company at around $55 per share. Could not find the source of the rumors.
February 14, 2017: Sarepta Therapeutic’s stock has formed a candle over candle reversal after Feuerstein said, “Sarepta Therapeutics is (Read More….)
February 1, 2017: Regeneron Pharmaceuticals, Inc. and Sanofi today announced that Health Canada approved Kevzara™ (sarilumab), an interleukin-6 (IL-6) receptor antibody, for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more biologic or non-biologic Disease-Modifying Anti-Rheumatic Drugs (DMARDs).
Kevzara (Read More….)
December 26, 2016: Hearing takeover rumors circulating about OpGen. The rumors are coming from the fact that Merck Global Health Innovation Fund disclosed a huge 37.5% stake in OpGen according to a schedule 13D filing.
November 16, 2016: Rodman & Renshaw/H.C. Wainwright reiterates a Buy rating on OpGen but cuts their price target from $3.25 (Read More….)